<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03917758</url>
  </required_header>
  <id_info>
    <org_study_id>GliRACo 1</org_study_id>
    <nct_id>NCT03917758</nct_id>
  </id_info>
  <brief_title>Antidiuretic Function Before and During Treatment With SGLT2 Inhibitors</brief_title>
  <acronym>GliRACo1</acronym>
  <official_title>Assessment of the Renin-angiotensin-aldosterone System (RAAS) and Antidiuretic Function in Patients With Type 2 Diabetes Before and During Treatment With Sodium-glucose Co-transporter 2 Inhibitors (SGLT2i): the GliRACo 1 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Turin, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Turin, Italy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects treated with Canagliflozin, Dapagliflozin and Empagliflozin obtained improvement on
      blood pressure values, body weight and cardiovascular mortality but pathophysiological
      explanations of these effects are not yet known.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The pathophysiological explanations of the cardiovascular improvement of patients treated
      with SGLT2i are not yet known: osmotic diuresis and natriuresis, direct effects of weight
      reduction, increased in nitric oxide release, oxidative stress reduction, local
      renin-angiotensin-aldosterone system (RAAS) inhibition are the supposed mechanism. In the
      Literature the diuretic effect of SGLT2i therapy seems to be even stronger than thiazide or
      thiazide-like drugs. However, it is not defined the role of SGLT2i on antidiuretic function
      (RAAS, brain natriuretic peptide-BNP and antidiuretic hormone-ADH). Defining this relation
      could be important for:

        -  knowing effect of SGLT2i on RAAS (drugs interferences are important particularly during
           case detection of primary aldosteronism);

        -  discovering antidiuretic response to SGLT2i treatment and interactions between RAAS, BNP
           and ADH on the volume improvement induced by this new antidiabetic drugs.

      In addition the aim of the study is to define effect of treatment on blood pressure and body
      composition.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2018</start_date>
  <completion_date type="Anticipated">October 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline of antidiuretic function parameters (BNP)</measure>
    <time_frame>Before starting SGLT2i and 30 days the starting SGLT2i therapy</time_frame>
    <description>Blood samples for BNP (pg/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline of antidiuretic function parameters (BNP)</measure>
    <time_frame>90 days after starting SGLT2i therapy</time_frame>
    <description>Blood samples for BNP (pg/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline of antidiuretic function parameters (vasopressin)</measure>
    <time_frame>Before starting SGLT2i and 30 days the starting SGLT2i therapy</time_frame>
    <description>Blood samples for Copeptin (pmol/L).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline of antidiuretic function parameters (vasopressin)</measure>
    <time_frame>90 days after starting SGLT2i therapy</time_frame>
    <description>Blood samples for Copeptin (pmol/L).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline of antidiuretic function parameters (osmolality)</measure>
    <time_frame>Before starting SGLT2i and 30 days the starting SGLT2i therapy</time_frame>
    <description>Samples for plasma osmolality (mOsm/Kg).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline of antidiuretic function parameters (osmolality)</measure>
    <time_frame>Before starting SGLT2i and 30 days the starting SGLT2i therapy</time_frame>
    <description>Samples for urinary osmolality (mOsm/Kg).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline of antidiuretic function parameters (osmolality)</measure>
    <time_frame>90 days after starting SGLT2i therapy</time_frame>
    <description>Samples for plasma osmolality (mOsm/Kg).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline of antidiuretic function parameters (osmolality)</measure>
    <time_frame>90 days after starting SGLT2i therapy</time_frame>
    <description>Samples for urinary osmolality (mOsm/Kg).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline of antidiuretic function parameters (sodium balance)</measure>
    <time_frame>Before starting SGLT2i and 30 days the starting SGLT2i therapy</time_frame>
    <description>Samples for serum sodium (mmol/L).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline of antidiuretic function parameters (sodium balance)</measure>
    <time_frame>90 days after starting SGLT2i therapy</time_frame>
    <description>Samples for serum sodium (mmol/L).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline of antidiuretic function parameters (sodium balance)</measure>
    <time_frame>Before starting SGLT2i and 30 days the starting SGLT2i therapy</time_frame>
    <description>Samples for urinary sodium (mmol/L).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline of antidiuretic function parameters (sodium balance)</measure>
    <time_frame>90 days after starting SGLT2i therapy</time_frame>
    <description>Samples for urinary sodium (mmol/L).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline of antidiuretic function parameters (potassium balance)</measure>
    <time_frame>Before starting SGLT2i and 30 days the starting SGLT2i therapy</time_frame>
    <description>Samples for serum potassium (mmol/L).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline of antidiuretic function parameters (potassium balance)</measure>
    <time_frame>90 days after starting SGLT2i therapy</time_frame>
    <description>Samples for serum potassium (mmol/L).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline of antidiuretic function parameters (potassium balance)</measure>
    <time_frame>Before starting SGLT2i and 30 days the starting SGLT2i therapy</time_frame>
    <description>Samples for urinary potassium (mmol/L).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline of antidiuretic function parameters (potassium balance)</measure>
    <time_frame>90 days after starting SGLT2i therapy</time_frame>
    <description>Samples for urinary potassium (mmol/L).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline of renin-angiotensin-aldosterone system parameters (renin)</measure>
    <time_frame>Before starting SGLT2i and 30 days the starting SGLT2i therapy</time_frame>
    <description>Blood samples for plasma renin activity (ng/mL/h).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline of renin-angiotensin-aldosterone system parameters (renin)</measure>
    <time_frame>90 days after starting SGLT2i therapy</time_frame>
    <description>Blood samples for plasma renin activity (ng/mL/h).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long term changes from baseline of renin-angiotensin-aldosterone system parameters aldosterone)</measure>
    <time_frame>Before starting SGLT2i and 30 days the starting SGLT2i therapy</time_frame>
    <description>Blood samples for aldosterone (pg/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long term changes from baseline of renin-angiotensin-aldosterone system parameters</measure>
    <time_frame>90 days after starting SGLT2i therapy</time_frame>
    <description>Blood samples for plasma renin activity (ng/mL/h) and aldosterone (pg/mL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline of blood pressure values (ABPM)</measure>
    <time_frame>Before starting SGLT2i and 90 days after the starting</time_frame>
    <description>Mean Systolic and Diastolic Blood Pressure (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline of body composition</measure>
    <time_frame>Before starting SGLT2i and 90 days after the starting</time_frame>
    <description>Variation of parameters of Bioelectrical Impedance Analysis (BIA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in basal glicemic control</measure>
    <time_frame>Before starting SGLT2i and 90 days after the starting</time_frame>
    <description>Blood samples for basal glucose (mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in long term glicemic control</measure>
    <time_frame>Before starting SGLT2i and 90 days after the starting</time_frame>
    <description>Blood samples for Glycated albumin (mmol/mol).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Arterial Hypertension</condition>
  <condition>Body Weight Changes</condition>
  <arm_group>
    <arm_group_label>Diabetic patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 diabetic patients candidate to treatment with SGLT2i in add-on to metformin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGLT2 inhibitor</intervention_name>
    <description>Start of the treatment with SGLT2i.</description>
    <arm_group_label>Diabetic patients</arm_group_label>
    <other_name>Dapagliflozin, Empagliflozin, Canagliflozin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diabetic patients;

          -  clinical indication to SGLT2i therapy.

        Exclusion Criteria:

          -  signs and symptoms of poor glycemic control (polydipsia, polyuria and weight loss);

          -  HbA1c &gt;10% or 86 mmol/mol;

          -  Body Mass Index (BMI) &gt; 40 Kg/m2;

          -  personal history of primary and secondary aldosteronism;

          -  personal history of heart failure;

          -  personal history of acute kidney injury;

          -  personal history of chronic kidney disease;

          -  personal history of liver cirrhosis;

          -  personal history of protein-wasting syndrome;

          -  personal history of renin secreting tumor;

          -  personal history of diabetes insipidus;

          -  personal history of syndrome of inappropriate antidiuresis (SIAD);

          -  personal history of hypocortisolism and hypercortisolism;

          -  therapy with Angiotensin Converting Enzyme inhibitors;

          -  therapy with Angiotensin Receptor Blockers;

          -  therapy with renin inhibitors;

          -  therapy with beta-blockers;

          -  therapy with alfa2-receptors agonists;

          -  therapy with Calcium Channel Blockers;

          -  therapy with diuretics;

          -  therapy with mineralocorticoid receptor antagonists;

          -  therapy with non steroidal and steroidal anti-inflammatory drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mauro M Maccario, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Endocrinology, Diabetology and Metabolism; University of Turin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ezio E Ghigo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Endocrinology, Diabetology and Metabolism; University of Turin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mauro M Maccario, MD</last_name>
    <phone>00390116709559</phone>
    <email>mauro.maccario@unito.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mirko M Parasiliti Caprino, MD, PhD</last_name>
    <phone>00390116335544</phone>
    <email>mirko.parasiliticaprino@unito.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mauro Maccario</name>
      <address>
        <city>Torino</city>
        <state>Piemonte</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauro M Maccario, MD</last_name>
      <phone>00390116709559</phone>
      <email>mauro.maccario@unito.it</email>
    </contact>
    <contact_backup>
      <last_name>Mirko M Parasiliti Caprino, MD, PhD</last_name>
      <phone>00390116335544</phone>
      <email>mirko.parasiliticaprino@unito.it</email>
    </contact_backup>
    <investigator>
      <last_name>Nunzia N Prencipe, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alessandro Maria A Berton, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chiara C Lopez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chiara C Bona, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea A Benso, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silvia S Grottoli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ezio E Ghigo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mauro M Maccario, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mirko M Parasiliti Caprino, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabio F Broglio, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Reed JW. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure. Vasc Health Risk Manag. 2016 Oct 27;12:393-405. eCollection 2016. Review.</citation>
    <PMID>27822054</PMID>
  </results_reference>
  <results_reference>
    <citation>Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.</citation>
    <PMID>26378978</PMID>
  </results_reference>
  <results_reference>
    <citation>Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013 Sep;15(9):853-62. doi: 10.1111/dom.12127. Epub 2013 Jun 5.</citation>
    <PMID>23668478</PMID>
  </results_reference>
  <results_reference>
    <citation>Shin SJ, Chung S, Kim SJ, Lee EM, Yoo YH, Kim JW, Ahn YB, Kim ES, Moon SD, Kim MJ, Ko SH. Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes. PLoS One. 2016 Nov 1;11(11):e0165703. doi: 10.1371/journal.pone.0165703. eCollection 2016.</citation>
    <PMID>27802313</PMID>
  </results_reference>
  <results_reference>
    <citation>Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, Fagan NM, Woerle HJ, Johansen OE, Broedl UC, von Eynatten M. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014 Feb 4;129(5):587-97. doi: 10.1161/CIRCULATIONAHA.113.005081. Epub 2013 Dec 13.</citation>
    <PMID>24334175</PMID>
  </results_reference>
  <results_reference>
    <citation>Boertien WE, Riphagen IJ, Drion I, Alkhalaf A, Bakker SJ, Groenier KH, Struck J, de Jong PE, Bilo HJ, Kleefstra N, Gansevoort RT. Copeptin, a surrogate marker for arginine vasopressin, is associated with declining glomerular filtration in patients with diabetes mellitus (ZODIAC-33). Diabetologia. 2013 Aug;56(8):1680-8. doi: 10.1007/s00125-013-2922-0. Epub 2013 Apr 28.</citation>
    <PMID>23624546</PMID>
  </results_reference>
  <results_reference>
    <citation>Nogueira-Silva L, Blanchard A, Curis E, Lorthioir A, Zhygalina V, Bergerot D, Baron S, Amar L, Bobrie G, Plouin PF, Ménard J, Azizi M. Deciphering the Role of Vasopressin in Primary Aldosteronism. J Clin Endocrinol Metab. 2015 Sep;100(9):3297-303. doi: 10.1210/JC.2015-2007. Epub 2015 Jul 10.</citation>
    <PMID>26161452</PMID>
  </results_reference>
  <results_reference>
    <citation>Pikkemaat M, Melander O, Bengtsson Boström K. Association between copeptin and declining glomerular filtration rate in people with newly diagnosed diabetes. The Skaraborg Diabetes Register. J Diabetes Complications. 2015 Nov-Dec;29(8):1062-5. doi: 10.1016/j.jdiacomp.2015.07.006. Epub 2015 Jul 9.</citation>
    <PMID>26321369</PMID>
  </results_reference>
  <results_reference>
    <citation>DeFronzo RA, Hompesch M, Kasichayanula S, Liu X, Hong Y, Pfister M, Morrow LA, Leslie BR, Boulton DW, Ching A, LaCreta FP, Griffen SC. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care. 2013 Oct;36(10):3169-76. doi: 10.2337/dc13-0387. Epub 2013 Jun 4.</citation>
    <PMID>23735727</PMID>
  </results_reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>April 7, 2019</study_first_submitted>
  <study_first_submitted_qc>April 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2019</study_first_posted>
  <last_update_submitted>December 26, 2019</last_update_submitted>
  <last_update_submitted_qc>December 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Turin, Italy</investigator_affiliation>
    <investigator_full_name>Mauro Maccario</investigator_full_name>
    <investigator_title>Medical Doctor, Professor</investigator_title>
  </responsible_party>
  <keyword>Sodium-Glucose Transporter 2 Inhibitors</keyword>
  <keyword>Renin-Angiotensin System</keyword>
  <keyword>Vasopressin</keyword>
  <keyword>Natriuretic Peptide, Brain</keyword>
  <keyword>Blood Pressure</keyword>
  <keyword>Body Composition</keyword>
  <keyword>Diabetes Mellitus, Type 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Body Weight Changes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol</mesh_term>
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Canagliflozin</mesh_term>
    <mesh_term>Sodium-Glucose Transporter 2 Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

